Construction of Recombinant PRV Expressing PRRSV Antigens and Evaluation of Their Protective Efficacy in Pigs Against Homologous Challenge
Shanghui Wang, Yunfei Liu, Longfei Han, Liguo Gao, Guangqiang Ye, Xiang Zhao, Yi Liu, Hongyang Liu, Zhaoxia Zhang, Changjiang WengBackground/Objectives: Porcine reproductive and respiratory syndrome virus (PRRSV) remains a major threat to the global swine industry, while the emergence of variant pseudorabies virus (PRV) strains has further complicated disease control in China. This study aimed to develop a PRV-based viral vector platform for PRRSV antigen delivery and evaluate its safety, immunogenicity, and protective efficacy. Methods: A five-gene-deleted variant PRV strain, PRV-JM-DF, was used as the vector backbone. Candidate genomic insertion sites and endogenous late promoters were systematically screened, followed by construction of recombinant PRVs expressing PRRSV GP2, GP3, GP4, GP5, and M individually or as tandem antigen constructs. Recombinant viruses were characterized for antigen expression, replication, and genetic stability. Safety and immunogenicity were initially evaluated in female BALB/c mice, and the leading candidates were further assessed for safety, immunogenicity, and protective efficacy in 18 Landrace pigs of either sex following challenge with highly pathogenic PRRSV HuN4. Results: The TK locus supported efficient foreign-gene expression, and pUL39 exhibited the highest activity among the tested endogenous late promoters. The recombinant viruses retained replication competence and genetic stability. Among the candidates, rPRV-C-4T induced robust PRRSV- and PRV-specific neutralizing antibody responses and showed no obvious adverse effects during the experimental observation period in pigs. Following HP-PRRSV HuN4 challenge, all rPRV-C-4T-immunized pigs survived and exhibited reduced viremia, viral shedding and tissue viral loads, together with markedly alleviated pathological lesions. Conclusions: rPRV-C-4T provided protection against homologous HP-PRRSV HuN4 challenge while maintaining PRV-directed immune responses, supporting its potential as a PRV-vectored multivalent vaccine candidate.